Last update 20 Mar 2025

Leucine/Sildenafil

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Leu Sil, Sildenafil/leucine
Target
PDE5A
Action
inhibitors
Mechanism
PDE5A inhibitors(Phosphodiesterase 5A inhibitors)
Therapeutic Areas
Endocrinology and Metabolic Disease
Active Indication-
Inactive Indication
Obesity
Originator Organization
Nusirt Sciences, Inc.Nusirt Sciences, Inc.
Active Organization-
Inactive Organization
NuSirt Biopharma, Inc.Nusirt Sciences, Inc.Nusirt Sciences, Inc.
Drug Highest PhasePendingPhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC28H38N6O11S
InChIKeyDEIYFTQMQPDXOT-UHFFFAOYSA-N
CAS Registry171599-83-0
View All Structures (2)

Related

1
Clinical Trials associated with Leucine/Sildenafil
NCT03364335
/ CompletedPhase 2
A Randomized, Double-blind, Placebo-controlled Study of Effects of Two Fixed-dose Leucine-sildenafil Combinations (NS-0300) or Two Fixed-dose Leucine-sildenafil-metformin Combinations (NS-0200) Versus Placebo on Body Weight in Obesity
100 Clinical Results associated with Leucine/Sildenafil
Login to view more data
100 Translational Medicine associated with Leucine/Sildenafil
Login to view more data
100 Patents (Medical) associated with Leucine/Sildenafil
Login to view more data
100 Deals associated with Leucine/Sildenafil
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
ObesityPhase 2
United States
Nusirt Sciences, Inc.Nusirt Sciences, Inc.
08 Jan 2018
ObesityPhase 2
United States
NuSirt Biopharma, Inc.
08 Jan 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT03364335 (CTgov)
Phase 2
Obesity
267
Placebo
(Placebo)
tiftnulkgd(cngdlswebq) = vwlmdlatxa etooqfvcan (dsyoiqrvur, ojgenrkhsy - ojugjzzfxd)
View more
-
27 Nov 2018
(Leu Sil 1.0mg)
tiftnulkgd(cngdlswebq) = mdpjrtvdoh etooqfvcan (dsyoiqrvur, jbuzdcyybf - dxpdizfiqm)
View more
AUA2016
Phase 2
Prostate Cancer, Hereditary, 7
First line
testosterone | PSA
75
(vfckqsjypl) = All-grade adverse events occurred in 91% vs 95% pts (TAK-385 vs LEU); the most common were hot flush and fatigue dcdumlxabz (fgiptjicvk )
View more
-
01 Apr 2016
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free